Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina.
Journal: 2006/August - World Journal of Gastroenterology
ISSN: 1007-9327
PUBMED: 16552814
Abstract:
OBJECTIVE
To evaluate the potential association between p53 codon 72 polymorphism and sporadic colorectal adenocarcinoma development,and human papillomavirus (HPV) infection.
METHODS
One-hundred and nine controls and 53 patients with colon cancer from the city of La Plata, Argentina were analyzed. p53 codon 72 genotypes and HPV infection were identified using allele-specific polymerase chain reaction and nested polymerase chain reaction, respectively.
RESULTS
The differences in the distribution of p53 codon 72 polymorphism between the cases and controls were statistically significant. The arginine allele had a prevalence of 0.65 in controls and 0.77 in cases. The corresponding odds ratio for the homozygous arginine genotype was 2.08 (95% CI, 1.06-4.05; P<0.05). Lack of association was found between p53 polymorphism and HPV infection in the set of adenocarcinomas.
CONCLUSIONS
The findings of the present study indicate that p53 codon 72 arginine homozygous genotype may represent a genetic predisposing factor for colon cancer development. However,further studies are needed in order to elucidate the role of p53 codon 72 polymorphism in colorectal cancer.
Relations:
Content
Citations
(20)
References
(28)
Diseases
(3)
Conditions
(1)
Drugs
(1)
Chemicals
(1)
Genes
(1)
Organisms
(2)
Processes
(2)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
World J Gastroenterol 12(9): 1426-1429

Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina

Luis Orlando Pérez, Martin Carlos Abba, Fernando Noel Dulout, Carlos Daniel Golijow, Centro de Investigaciones en Genética Básica y Aplicada, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, Calle 60 y 118 S/N, B 1900 AVW, La Plata, Argentina
Correspondence to: Pérez, Luis Orlando, Centro de Invest-igaciones en Genética Básica y Aplicada, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, Calle 60 y 118 S/N, B 1900 AVW, La Plata, Argentina. ra.moc.oohay@siulzerp

Telephone: +54-221-4211799 Fax: +54-221-4211799

Luis Orlando Pérez, Martin Carlos Abba, Fernando Noel Dulout, Carlos Daniel Golijow, Centro de Investigaciones en Genética Básica y Aplicada, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, Calle 60 y 118 S/N, B 1900 AVW, La Plata, Argentina
Correspondence to: Pérez, Luis Orlando, Centro de Invest-igaciones en Genética Básica y Aplicada, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, Calle 60 y 118 S/N, B 1900 AVW, La Plata, Argentina. ra.moc.oohay@siulzerp

Telephone: +54-221-4211799 Fax: +54-221-4211799

Received 2005 Sep 13; Revised 2005 Oct 1; Accepted 2005 Oct 26.

Abstract

AIM: To evaluate the potential association between p53 codon 72 polymorphism and sporadic colorectal adenocarcinoma development, and human papillomavirus (HPV) infection.

METHODS: One-hundred and nine controls and 53 patients with colon cancer from the city of La Plata, Argentina were analyzed. p53 codon 72 genotypes and HPV infection were identified using allele-specific polymerase chain reaction and nested polymerase chain reaction, respectively.

RESULTS: The differences in the distribution of p53 codon 72 polymorphism between the cases and controls were statistically significant. The arginine allele had a prevalence of 0.65 in controls and 0.77 in cases. The corresponding odds ratio for the homozygous arginine genotype was 2.08 (95% CI, 1.06-4.05; P<0.05). Lack of association was found between p53 polymorphism and HPV infection in the set of adenocarcinomas.

CONCLUSION: The findings of the present study indicate that p53 codon 72 arginine homozygous genotype may represent a genetic predisposing factor for colon cancer development. However, further studies are needed in order to elucidate the role of p53 codon 72 polymorphism in colorectal cancer.

Keywords: p53 codon 72 polymorphism, Human papillomavirus, Colorectal cancer
Abstract

Footnotes

Supported by the National University of La Plata (grant v-138), Argentina

S- Editor Wang J L-Editor Zhu LH E- Editor Zhang Y

Footnotes

References

  • 1. Ferlay J, Bray F, Pisani P, Parkin DM GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARC Press;; 2004. [PubMed][Google Scholar]
  • 2. Calvert PM, Frucht HThe genetics of colorectal cancer. Ann Intern Med. 2002;137:603–612.[PubMed][Google Scholar]
  • 3. Gazelle GS, McMahon PM, Scholz FJScreening for colorectal cancer. Radiology. 2000;215:327–335.[PubMed][Google Scholar]
  • 4. Nakamura YIsolation of p53-target genes and their functional analysis. Cancer Sci. 2004;95:7–11.[PubMed][Google Scholar]
  • 5. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski GTwo polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–1100.[Google Scholar]
  • 6. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho HAnalysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis. 1996;17:261–264.[PubMed][Google Scholar]
  • 7. Langerød A, Bukholm IR, Bregård A, Lønning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Børresen-Dale ALThe TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002;11:1684–1688.[PubMed][Google Scholar]
  • 8. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner ASelective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia. 2004;6:529–535.[Google Scholar]
  • 9. Lung FW, Lee TM, Shu BC, Chang FHp53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol. 2004;130:728–732.[PubMed][Google Scholar]
  • 10. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S, Hall J, Guino E, Peinado MA, Capella G, et al A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004;23:1954–1956.[PubMed][Google Scholar]
  • 11. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks LRole of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–234.[PubMed][Google Scholar]
  • 12. McGregor B, Byrne P, Kirgan D, Albright J, Manalo P, Hall MConfirmation of the association of human papillomavirus with human colon cancer. Am J Surg. 1993;166:738–40; discussion 741-2.[PubMed][Google Scholar]
  • 13. Cheng JY, Sheu LF, Meng CL, Lee WH, Lin JCDetection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction. Gut. 1995;37:87–90.[Google Scholar]
  • 14. Lee YM, Leu SY, Chiang H, Fung CP, Liu WTHuman papillomavirus type 18 in colorectal cancer. J Microbiol Immunol Infect. 2001;34:87–91.[PubMed][Google Scholar]
  • 15. Bodaghi S, Yamanegi K, Xiao SY, Da Costa M, Palefsky JM, Zheng ZMColorectal papillomavirus infection in patients with colorectal cancer. Clin Cancer Res. 2005;11:2862–2867.[Google Scholar]
  • 16. Pérez LO, Abba MC, Laguens RM, Golijow CDAnalysis of adenocarcinoma of the colon and rectum: detection of human papillomavirus (HPV) DNA by polymerase chain reaction. Colorectal Dis. 2005;7:492–495.[PubMed][Google Scholar]
  • 17. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol. 2001;109:25–34.[PubMed]
  • 18. Miller SA, Dykes DD, Polesky HFA simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.[Google Scholar]
  • 19. Abba MC, Villaverde LM, Gómez MA, Dulout FN, Laguens MR, Golijow CDThe p53 codon 72 genotypes in HPV infection and cervical disease. Eur J Obstet Gynecol Reprod Biol. 2003;109:63–66.[PubMed][Google Scholar]
  • 20. Evander M, Edlund K, Bodén E, Gustafsson A, Jonsson M, Karlsson R, Rylander E, Wadell GComparison of a one-step and a two-step polymerase chain reaction with degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women. J Clin Microbiol. 1992;30:987–992.[Google Scholar]
  • 21. Golijow CD, Mourón SA, Gómez MA, Dulout FNDifferences in K-ras codon 12 mutation frequency between "high-risk" and "low-risk" HPV-infected samples. Gynecol Oncol. 1999;75:108–112.[PubMed][Google Scholar]
  • 22. Golijow CD, Abba M, Mourón SA, Gómez MA, Güercci A, Dulout FNDetection of c-erbB-2 gene amplification in cervical scrapes positive for human papillomavirus (HPV) Cancer Invest. 2001;19:678–683.[PubMed][Google Scholar]
  • 23. Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A, Beckman LIs p53 polymorphism maintained by natural selection. Hum Hered. 1994;44:266–270.[PubMed][Google Scholar]
  • 24. Ojeda JM, Ampuero S, Rojas P, Prado R, Allende JE, Barton SA, Chakraborty R, Rothhammer Fp53 codon 72 polymorphism and risk of cervical cancer. Biol Res. 2003;36:279–283.[PubMed][Google Scholar]
  • 25. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MCHomozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol. 2005;11:289–292.[Google Scholar]
  • 26. Lu XM, Zhang YM, Lin RY, Liang XH, Zhang YL, Wang X, Zhang Y, Wang Y, Wen Hp53 polymorphism in human papillomavirus-associated Kazakh's esophageal cancer in Xinjiang, China. World J Gastroenterol. 2004;10:2775–2778.[Google Scholar]
  • 27. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, et al A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000;25:47–54.[PubMed][Google Scholar]
  • 28. Kaelin WGThe emerging p53 gene family. J Natl Cancer Inst. 1999;91:594–598.[PubMed][Google Scholar]
  • 29. Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, Tada M, Menichini P, Abbondandolo A, Fronza GCharacterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene. 2003;22:5252–5260.[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.